3B Blackbio Dx Limited (NSE:3BBLACKBIO)

Market Cap	10.75B -26.1%
Revenue (ttm)	1.42B +47.1%
Net Income	585.86M +22.8%
EPS	69.94 +25.7%
Shares Out	n/a
PE Ratio	18.35
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	52,053
Open	1,228.00
Previous Close	1,201.50
Day's Range	1,199.90 - 1,441.50
52-Week Range	1,085.00 - 1,424.70
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	May 29, 2026

About 3B Blackbio Dx

3B Blackbio Dx Limited engages in the design, development, manufacturing, and commercialization of molecular diagnostic solutions for infectious diseases, oncology, human genetics and antimicrobial resistance in India. The company offers qPCR-based and lateral flow assays rapid tests and Next Gen Sequencing -based molecular diagnostic kits for accurate and reliable testing on patient samples under the TRUPCR, TRUNGS, TRURAPID, brand for testing on patient samples to diagnostics labs. It also offers agrochemical products; technical support and t...

• Industry: Agricultural Chemicals
• Founded: 1972
• Employees: 85
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: 3BBLACKBIO

Financial Performance

In fiscal year 2026, 3B Blackbio Dx's revenue was 1.42 billion, an increase of 47.11% compared to the previous year's 964.69 million. Earnings were 585.86 million, an increase of 22.84%.